Repligen Corporation $RGEN Shares Purchased by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio raised its stake in Repligen Corporation (NASDAQ:RGEN) by 16.9% during the first quarter, according to its most recent disclosure with the SEC. The fund owned 52,811 shares of the biotechnology company’s stock after buying an additional 7,649 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Repligen were worth $6,222,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. NewEdge Wealth LLC grew its position in shares of Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 75 shares during the last quarter. UMB Bank n.a. increased its holdings in shares of Repligen by 13.8% in the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock worth $124,000 after acquiring an additional 92 shares during the period. CANADA LIFE ASSURANCE Co lifted its position in Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the last quarter. Coldstream Capital Management Inc. lifted its position in Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 101 shares during the last quarter. Finally, Itau Unibanco Holding S.A. boosted its stake in Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock valued at $62,000 after purchasing an additional 104 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the subject of several recent analyst reports. Jefferies Financial Group restated a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. Roth Capital assumed coverage on Repligen in a report on Friday, April 17th. They set a “buy” rating and a $160.00 price target on the stock. JPMorgan Chase & Co. reduced their price objective on Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Barclays increased their price objective on Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, Citigroup upgraded Repligen to a “buy” rating in a research report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $165.36.

Repligen Stock Performance

RGEN stock opened at $145.34 on Wednesday. The company has a market capitalization of $8.20 billion, a P/E ratio of 161.49, a PEG ratio of 2.53 and a beta of 1.06. The company has a 50-day simple moving average of $132.95 and a 200 day simple moving average of $131.88. Repligen Corporation has a fifty-two week low of $100.99 and a fifty-two week high of $175.77. The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.45 by $0.09. The firm had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 6.73% and a return on equity of 4.88%. Repligen’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter last year, the company earned $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Sell-side analysts predict that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, CFO Jason K. Garland sold 733 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $145.00, for a total value of $106,285.00. Following the completion of the transaction, the chief financial officer directly owned 19,359 shares in the company, valued at $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.60% of the company’s stock.

Trending Headlines about Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Q2 beat expectations: Revenue rose 12% year over year to $204.1 million, exceeding the roughly $201.6 million consensus estimate, while adjusted EPS of $0.54 surpassed expectations of approximately $0.45. Organic revenue growth was 13%, reflecting continued order momentum. Repligen Posts Better-Than-Expected Sales in Q2 CY2026
• Positive Sentiment: Higher 2026 guidance: Repligen raised its organic revenue-growth forecast to 10.5%-13.5% and adjusted diluted EPS guidance to $2.03-$2.09, above the approximately $2.00 analyst consensus. Total reported revenue is projected at $813 million-$835 million. Repligen Reports Q2 Results and Updates 2026 Guidance
• Positive Sentiment: Adjusted margins improved: Adjusted operating income increased 55% to $34 million, and adjusted operating margin expanded to 16.7% from 12.0% a year earlier. Management also cited better visibility into second-half performance.
• Positive Sentiment: BioLife Solutions acquisition adds a strategic catalyst: Repligen said its planned acquisition should strengthen its cell-therapy platform and potentially contribute to revenue growth, margin expansion and adjusted EPS over time. Repligen Jumps After Q2 Beat and Higher 2026 Outlook
• Positive Sentiment: Analyst support: William Blair maintained a Buy rating, citing the quarterly beat, raised guidance and broad-based demand strength. Recent analyst targets have a reported median of $160.
• Neutral Sentiment: Repligen ended June with $810 million in cash, cash equivalents and marketable securities, providing financial flexibility for operations and the pending acquisition.
• Negative Sentiment: GAAP profitability declined: Net income fell to $5.0 million from $14.9 million, and GAAP diluted EPS decreased to $0.09 from $0.26. The decline was influenced by higher taxes and other adjustments, while GAAP operating income was essentially flat.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.